<DOC>
	<DOCNO>NCT01393756</DOCNO>
	<brief_summary>The purpose study ass efficacy association Lenalidomide ( Revlimid ) R-CHOP ( Rituximab , Cyclophosphamide , Doxorubicin , vincristine Prednisone ) population patient follicular lymphoma measure response rate end treatment .</brief_summary>
	<brief_title>Revlimid Dose 25 mg Association With ( R-CHOP ) Treatment Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Patients follicular lymphoma , ( WHO ) grade 1 , 2 3a least one follow sign require initiation treatment : Bulky disease accord GELF criterion : nodal extranodal mass &gt; 7cm great diameter B symptom Elevated serum ( LDH ) beta 2microglobulin Involvement least 3 nodal site ( &gt; 3cm ) Symptomatic spleen enlargement Compressive syndrome Pleural peritoneal effusion Aged 18 70 year WHO performance status 0 , 1 2 Signed inform consent Life expectancy ≥ 90 day ( 3 month ) . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 25 mIU/mL 3 day start study drug must either commit continued abstinence heterosexual intercourse ( confirm monthly basis ) begin one effective method birth control , least four week start take lenalidomide , maintain method throughout entire duration study drug therapy ( include dose interruption ) , four week end study treatment lenalidomide , even amenorrhea . FCBP must also agree pregnancy test least every three week must counsel minimum every three week pregnancy precaution risk fetal exposure . Men must agree father child agree use condom throughout study drug therapy , dose interruption , one week cessation study drug therapy , partner pregnant child bear potential . Men must also agree donate semen study drug therapy one week end study drug therapy . Men must counsel minimum every 4 week pregnancy precaution risk fetal exposure . All subject must abstain donate blood take study drug therapy one week follow discontinuation study drug therapy . Agree share study drug another person return unused study drug investigator . A female patient consider childbearing potential unless meet least one follow criterion 1 ) Age ≥ 50 year naturally amenorrhoeic ≥ 1 year ( amenorrhoea follow cancer therapy rule childbearing potential ) ; 2 ) Premature ovarian failure confirm specialist gynaecologist 3 ) Previous bilateral salpingooophorectomy ( BSO ) , hysterectomy , 4 ) XY genotype , turner syndrome , uterine agenesis . Previous treatment immunotherapy chemotherapy : Chlorambucil Cyclophosphamide per o alone less 6 month , stop one year inclusion Rituximab alone less three month , stop one year inclusion Previous radiotherapy except localized one lymph node area Other type lymphoma : Burkitt , T cell , lymphocytic , CD 20 negative Central nervous system meningeal involvement Contraindication drug contain chemotherapy regimen ( HIV ) disease , active hepatitis B C Any serious active disease comorbid medical condition ( accord investigator 's decision ) Any follow laboratory abnormality . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) . Platelet count &lt; 100,000/mm3 ( 100 x 109/L ) . Serum ( SGOT/AST ) ( SGPT/ALT ) 5.0 x upper limit normal ( ULN ) . Serum total bilirubin &gt; 2.0 mg/dL ( 34 µmol/L ) , except case hemolytic anemia . Calculated creatinine clearance ( CockcroftGault formula ) &lt; 50 mL /min Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥ 3 year Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant lactating female . Prior ≥ Grade 3 allergic reaction/hypersensitivity thalidomide . Prior ≥ Grade 3 rash desquamating ( blister ) rash take thalidomide . Subjects ≥ Grade 2 neuropathy . Prior use lenalidomide . Use standard experimental anticancer drug therapy within 28 day initiation ( Day 1 ) study drug therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>